AMZN
Amazon.com, Inc.
AMZN has a slight edge over CRI overall, supported by stronger modeled upside and lower modeled downside.
CRI
Carter's, Inc.
CRI offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CRI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.6x | $33.87 | — |
| Cheap | 8.6x | $51.89 | +53% |
| Forward | 10x | $33.87 | — |
| Fair | 12x | $74.79 | +121% |
| Expensive | 18x | $107 | +215% |
Historical ranges are pointers, not guarantees.
CRI has the edge over AMZN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CRI on the outlook, with more favorable revenue expectations.
CRI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect CRI's earnings to grow and its profitability to improve, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CRI on earnings, with more consistent year-over-year improvement.
CRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.24 | -46% |
| Q3 2026 | $6.03 | +145% |
| Q2 2026 | $5.35 | +42% |
| Q1 2026 | $2.49 | -45% |
| Q4 2025 | $2.53 | -51% |
| Q3 2025 | $2.46 | -61% |
| Q2 2025 | $3.76 | -42% |
| Q1 2025 | $4.51 | -29% |
| Q4 2024 | $5.12 | -18% |
CRI earned $6.03 per share over the past year, up 145% from the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CRI on profitability, with a higher operating margin.
CRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $752.5M | -0.7% |
| Q2 2026 | $615.5M | +5.2% |
| Q1 2026 | $681.1M | +8.1% |
| Q4 2025 | $925.5M | +7.6% |
| Q3 2025 | $757.8M | -0.1% |
| Q2 2025 | $585.3M | +3.7% |
| Q1 2025 | $629.8M | -4.8% |
| Q4 2024 | $859.7M | +0.2% |
CRI's revenue has picked up after two years of holding roughly level: $752M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +3.6 points |
| Q2 2026 | 23% | +22 points |
| Q1 2026 | 4.2% | 0 points |
| Q4 2025 | 9.2% | -0.5 points |
| Q3 2025 | 3.8% | -6.3 points |
| Q2 2025 | 0.7% | -6.3 points |
| Q1 2025 | 4.1% | -4.2 points |
| Q4 2024 | 9.7% | -6.2 points |
CRI's operating margin was 7.4% last quarter, up 3.6 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$117.4M | +$26.7M |
| Q2 2026 | $190M | +688% |
| Q1 2026 | -$543K | +$58.4M |
| Q4 2025 | $247.6M | -8.6% |
| Q3 2025 | -$144.1M | -$48.4M |
| Q2 2025 | $24.1M | -77% |
| Q1 2025 | -$59M | -$21.4M |
| Q4 2024 | $270.9M | -11% |
CRI has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +36.1K shares |
| 1 year | +0.5% | +192K shares |
| 3 years | -2.2% | -806K shares |
| 5 years | -18% | -7.8M shares |
| Available history | -20% | -9.1M shares |
CRI has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16.7M |
| Q2 2024 | $24.8M |
| Q1 2024 | $9M |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.3x | Very low |
CRI has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 29.2 | Neutral |
CRI's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CRI PE vs Consumer Cyclical Sector
| Metric | CRI | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 18x | 69% below |
| PE % | 1 | 47 | 46 pts below |
CRI has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CRI on trend strength, trading above more of its moving averages.
CRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.1 | 5.5% above |
| 20 week MA | $34.7 | 2.5% below |
| 50 week MA | $35.7 | 5% below |
| 100 week MA | $36.0 | 6% below |
| 200 week MA | $52.7 | 36% below |
CRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 36% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CRI on returns for 2026, with the stronger performance.
CRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.1 | $95.0 | -14% |
| 2021 | $95.0 | $98.7 | +3.9% |
| 2022 | $98.7 | $73.4 | -26% |
| 2023 | $73.4 | $74.9 | +2.1% |
| 2024 | $74.9 | $54.4 | -27% |
| 2025 | $54.4 | $31.7 | -42% |
| 2026 YTD | $31.7 | $33.9 | +6.9% |
CRI has finished lower in four of the last six years. It's up 6.9% so far in 2026.